UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NEW ORLEANS, La., Nov. 12, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 9, 2017 to file lead plaintiff applications in securities class action lawsuit against Impax Laboratories Inc. (Nasdaq:IPXL), if they purchased the Company’s securities between February 25, 2014 through November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased shares of Impax and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 9, 2017.
About the Lawsuit
Impax and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Impax, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
